Skip to main content

Table 2 Comparative efficacy and safety between infliximab and vedolizumab in patients with ulcerative colitis

From: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Outcome Treatment Participants, N Infliximab and biosimilars, estimate (95% CI)a Heterogeneity (%)
Efficacy: Induction phase (Week 6)
Clinical responseb Infliximab 242 67% (61%, 73%) 0
  Vedolizumab 608 52% (46%, 58%) 78
Mucosal healing Infliximab 242 61% (55%, 67%) 0
Clinical remissionb Infliximab 242 36% (31%, 43%) 0
  Vedolizumab 608 21% (16%, 28%) 82
Efficacy: Maintenance phase (Week 50 to 54)
Clinical responseb Infliximab 198 54% (43%, 65%) 62
  Vedolizumab 282 63% (56%, 69%) 51
Mucosal healing Infliximab 198 49% (43%, 56%) 2
  Vedolizumab 665 49% (42%, 57%) 78
Clinical remissionb Infliximab 198 43% (33%, 54%) 60
  Vedolizumab 665 39% (33%, 46%) 73
Safety (≤ 1 year)
Any AE Infliximab 214 75% (60%, 86%) 86
  Vedolizumab 543 64% (60%, 68%) 44
Any SAE Infliximab 214 12% (6%, 23%) 72
  Vedolizumab 543 11% (9%, 14%) 0
Any infection Infliximab 214 21% (8%, 43%) 91
  Vedolizumab 543 26% (22%, 29%) 14
Any serious infection Infliximab 242 2% (1%, 5%) 0
  Vedolizumab 489 2% (1%, 3%) 0
Discontinuation due to AE Infliximab 214 4% (1%, 14%) 0
  Vedolizumab 667 5% (3%, 7%) 0
Discontinuation due to lack of efficacy Vedolizumab 667 15% (10%, 22%) 82
  1. a Random-effects model
  2. b Based on total Mayo score
  3. All results reported as the proportion of patients achieving the response
  4. AE Adverse event, CDAI Crohn’s disease activity index, CI Confidence interval, SAE Serious adverse event